Oral ONC201 in Adult Recurrent Glioblastoma

Trial Profile

Oral ONC201 in Adult Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Oncoceutics
  • Most Recent Events

    • 29 Mar 2017 According to an Oncoceutics media release, results from the first cohort of patients will be reported in scientific forums throughout this year.
    • 29 Mar 2017 According to an Oncoceutics media release, Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute are now enrolling patients in an expansion of the clinical trial in adult recurrent glioblastoma.
    • 19 Mar 2017 Planned number of patients changed from 66 to 53.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top